Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines?
Scientific societies have provided guidelines to reduce PSA-specific harms. We studied the potential non-compliance of PSA testing with current guidelines in general practice. A cross-sectional study of a random sample of 1291 patients with a PSA test was performed between January and April 2018 in...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/12/2650 |
| _version_ | 1797529958391742464 |
|---|---|
| author | Mari Carmen Bernal-Soriano Lucy Anne Parker Maite López-Garrigós Ildefonso Hernández-Aguado Luis Gómez-Pérez Juan-Pablo Caballero-Romeu María Pastor-Valero Nuria García Rocío Alfayate-Guerra Blanca Lumbreras |
| author_facet | Mari Carmen Bernal-Soriano Lucy Anne Parker Maite López-Garrigós Ildefonso Hernández-Aguado Luis Gómez-Pérez Juan-Pablo Caballero-Romeu María Pastor-Valero Nuria García Rocío Alfayate-Guerra Blanca Lumbreras |
| author_sort | Mari Carmen Bernal-Soriano |
| collection | DOAJ |
| description | Scientific societies have provided guidelines to reduce PSA-specific harms. We studied the potential non-compliance of PSA testing with current guidelines in general practice. A cross-sectional study of a random sample of 1291 patients with a PSA test was performed between January and April 2018 in primary health care. Patients with a previous prostate cancer diagnosis or those who were being followed-up for previous high PSA values were excluded. Two independent researchers classified whether each test was potentially non-compliant with recommendations. We estimated frequencies of potentially non-compliant PSA determinations and calculated prevalence ratios (PR) to assess their relationship with possible explanatory variables. A total of 66% (95% CI: 62–69%) of PSA requests in asymptomatic patients were potentially non-compliant with the current guideline. This was associated with having a previous diagnosis of neoplasm (PR adjusted by age and life expectancy: 1.18; 95% CI: 1.02–1.37) as well as being a current consumer of tobacco, alcohol, or other drugs (PR: 0.80; 95% CI: 0.67–0.97). Real world data shows that patients are still frequently exposed to overdiagnosis risk with a PSA potentially non-compliant with recommendations. Patients diagnosed with another neoplasm or non-consumers of toxic substances were more exposed, probably due to increased contact with doctors or health-seeking behaviour. |
| first_indexed | 2024-03-10T10:21:16Z |
| format | Article |
| id | doaj.art-39818be37cd14d54b05756a8608c4046 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T10:21:16Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-39818be37cd14d54b05756a8608c40462023-11-22T00:22:10ZengMDPI AGJournal of Clinical Medicine2077-03832021-06-011012265010.3390/jcm10122650Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines?Mari Carmen Bernal-Soriano0Lucy Anne Parker1Maite López-Garrigós2Ildefonso Hernández-Aguado3Luis Gómez-Pérez4Juan-Pablo Caballero-Romeu5María Pastor-Valero6Nuria García7Rocío Alfayate-Guerra8Blanca Lumbreras9Department of Public Health, University Miguel Hernández de Elche, 03550 Alicante, SpainDepartment of Public Health, University Miguel Hernández de Elche, 03550 Alicante, SpainCIBER de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, SpainDepartment of Public Health, University Miguel Hernández de Elche, 03550 Alicante, SpainUrology Department, University Hospital of San Juan de Alicante, 03550 Alicante, SpainDepartment of Urology, University General Hospital of Alicante, 03010 Alicante, SpainDepartment of Public Health, University Miguel Hernández de Elche, 03550 Alicante, SpainDepartment of Urology, University General Hospital of Alicante, 03010 Alicante, SpainClinical Laboratory Department, University General Hospital of Alicante, 03010 Alicante, SpainDepartment of Public Health, University Miguel Hernández de Elche, 03550 Alicante, SpainScientific societies have provided guidelines to reduce PSA-specific harms. We studied the potential non-compliance of PSA testing with current guidelines in general practice. A cross-sectional study of a random sample of 1291 patients with a PSA test was performed between January and April 2018 in primary health care. Patients with a previous prostate cancer diagnosis or those who were being followed-up for previous high PSA values were excluded. Two independent researchers classified whether each test was potentially non-compliant with recommendations. We estimated frequencies of potentially non-compliant PSA determinations and calculated prevalence ratios (PR) to assess their relationship with possible explanatory variables. A total of 66% (95% CI: 62–69%) of PSA requests in asymptomatic patients were potentially non-compliant with the current guideline. This was associated with having a previous diagnosis of neoplasm (PR adjusted by age and life expectancy: 1.18; 95% CI: 1.02–1.37) as well as being a current consumer of tobacco, alcohol, or other drugs (PR: 0.80; 95% CI: 0.67–0.97). Real world data shows that patients are still frequently exposed to overdiagnosis risk with a PSA potentially non-compliant with recommendations. Patients diagnosed with another neoplasm or non-consumers of toxic substances were more exposed, probably due to increased contact with doctors or health-seeking behaviour.https://www.mdpi.com/2077-0383/10/12/2650prostate-specific antigenclinical practice guidelinesprostate cancerscreening |
| spellingShingle | Mari Carmen Bernal-Soriano Lucy Anne Parker Maite López-Garrigós Ildefonso Hernández-Aguado Luis Gómez-Pérez Juan-Pablo Caballero-Romeu María Pastor-Valero Nuria García Rocío Alfayate-Guerra Blanca Lumbreras Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? Journal of Clinical Medicine prostate-specific antigen clinical practice guidelines prostate cancer screening |
| title | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
| title_full | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
| title_fullStr | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
| title_full_unstemmed | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
| title_short | Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines? |
| title_sort | do the prostate specific antigen psa tests that are ordered in clinical practice adhere to the pertinent guidelines |
| topic | prostate-specific antigen clinical practice guidelines prostate cancer screening |
| url | https://www.mdpi.com/2077-0383/10/12/2650 |
| work_keys_str_mv | AT maricarmenbernalsoriano dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT lucyanneparker dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT maitelopezgarrigos dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT ildefonsohernandezaguado dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT luisgomezperez dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT juanpablocaballeroromeu dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT mariapastorvalero dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT nuriagarcia dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT rocioalfayateguerra dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines AT blancalumbreras dotheprostatespecificantigenpsateststhatareorderedinclinicalpracticeadheretothepertinentguidelines |